| INTRODUCTION
In healthy subjects, endogenous GH is synthesized by the somatotrophic cells in the pituitary gland under hypothalamic control, and a complex regulatory system controls the pulsatile release of fine-tuned GH bursts into the peripheral circulation. None of the previously or currently recommended GH therapies to treat children with GH deficiency (GHD) or adult GHD (AGHD) have been able to mimic this complex, endogenous, physiologically regulated system. Nevertheless, these nonphysiological replacement therapies have been used for several decades-in particular, daily recombinant human GH has been used since 1985-and have been shown to promote linear growth without safety concerns. 1 However, clinical studies have shown poor compliance by children with a once-daily injection regimen of GH, 2, 3 attributed in part to difficulties with injections. 4 In addition, it has been reported that GH compliance positively affects growth velocity. 5, 6 It is possible that longer-acting GH preparations allowing for reduced injection frequency could improve treatment adherence, although this has not been demonstrated. If treatment adherence is greater with reduced injection frequency, this could potentially result in improved long-term treatment outcomes. This technology of using a conjugated linker was not associated with any significant tolerability issues with insulin or GLP-1.
9,10
The safety, pharmacokinetics (PK) and IGF-I profiles generated by once-weekly dosing of somapacitan have been studied in healthy adult male subjects 11 and patients with AGHD. 12 The results showed that a once-weekly dosing regimen for somapacitan was feasible. 11, 12 The current study was a single-dose trial of somapacitan in children with GHD.
| SUBJECTS AND METHODS

| Patients
The study enrolled prepubertal boys and girls (Tanner stage 1; boys aged ≥6-<13 years; girls aged ≥6-<12 years) with body weight ≥16.0-≤50.0 kg and a confirmed diagnosis of GHD based on two different GH stimulation tests (peak GH ≤7.0 ng/mL dose of somapacitan and to compare local tolerability with once-daily GH given for 7 days in children with GHD. PD were assessed using serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3).
| Trial design and procedures
Four cohorts, each including eight children with GHD, were investigated.
Within each cohort, subjects were randomized 3:1, using a telephonebased interactive voice/web response system, to treatment with either a single dose of somapacitan or 7 days of once-daily injections of GH.
Somapacitan use was investigated at four sequential dose levels: 0.02, 0.04, 0.08 and 0.16 mg/kg, and GH was given at 0.030 mg/kg/d.
The patients attended a screening visit, followed by a GH washout period of 7-10 days immediately before the first injection with trial product. The study protocol involved a 3-day in-house stay, followed by a 7-day ex-house period and a final follow-up visit scheduled 28- 15 and IGFBP-3 SDS were calculated using reference data supplied by the kit manufacturer (Immuno Diagnostic Systems).
| Safety assessments
| Trial procedures and assay methods
Serum samples for determination of antibodies against somapacitan or hGH were collected at baseline (prior to treatment start), end of treatment (168 hours after the last dose) and at the follow-up visit.
Antibodies against somapacitan or against hGH were evaluated in patients treated with the respective drugs using a bridging ELISA in each case. Both assays were developed and validated by Novo Nordisk A/S (Maaloev, Denmark) (for details see Rasmussen et al.
12
). Laboratory safety assessments were performed as follows: haematological (white blood cell count, red blood cell count, haemoglobin, haematocrit, 
| Statistical analysis
A significance level of 5% was used without adjustment for multiple testing. All tests were two-sided superiority tests. Dose proportionality was investigated using a linear regression model with the logtransformed end-point as the dependent variable and log-transformed dose as covariate. Other end-points were evaluated using descriptive statistics. Sample size was not based on formal calculations but was determined to expose the lowest possible number of patients to somapacitan while enabling adequate assessment of safety, PK and PD data to continue to the next dose level.
| Pharmacokinetics
The following PK parameters were determined using standard noncompartmental methods: the somapacitan peak plasma concentration (C max ), time to C max (t max ), area under the curve (AUC) from 0-168 hours after dosing (AUC (0-168 h) ; somapacitan only) and terminal half-life (t ½ ).
AUC for 0-24 hours (AUC (0-24 h) ) was determined for Norditropin ® only.
All evaluations for somapacitan were based on evaluation of data collected for up to 7 days (168 hours) and at end of trial. All PK parameters were analysed using descriptive statistics. Dose proportionality was investigated using a linear regression model with the log-transformed end-point (AUC (0-168 h) or C max ) as the dependent variable and the logtransformed dose as covariate. In descriptive statistics and all formal statistical testing, all patients receiving Norditropin ® (n=8) were pooled into one dose group, irrespective of the allocated dose cohort.
| Pharmacodynamics
The following PD end-points were calculated for IGF-I and IGFBP-3: and C max values were log-transformed before analysis. Mean ratios/ differences for somapacitan doses and mean ratios/differences for somapacitan vs Norditropin ® were estimated with corresponding 95% confidence intervals (CIs) and P-values.
| RESULTS
| Patient disposition and characteristics
A total of 32 children with GHD (23 with idiopathic GHD and nine with organic GHD) were randomized, exposed and completed the trial (somapacitan: 24 children; Norditropin ® : 8 children). No children withdrew from the trial. Race and ethnicity were as follows:
28 children were Caucasian, one was reported as "other" and details were not reported for three patients in France due to local regulations. The proportion of boys (n=23) was greater than girls (n=9), except in the somapacitan 0.04 mg/kg group (one boy, five girls). In the 
| Safety
Somapacitan administered s.c. to children with GHD was well tolerated at all doses investigated (0.02-0.16 mg/kg), with no clinically significant safety or local tolerability issues identified. No serious AEs were reported, and there were no AEs leading to withdrawal.
A total of 19 AEs were reported in 11 children (46%) treated with somapacitan, and two AEs (nausea and vomiting) were reported in one child (13%) following once-daily Norditropin ® SimpleXx ® treatment. The majority of events were single events reported in one or two children.
AEs occurring in ≥5% of children are listed in Table 2 . With somapacitan, the AEs reported in at least two children were nasopharyngitis, headache and vomiting; AEs reported in one child each were general disorders and administration site conditions (n=3), infections and infestations (n=4), and myalgia, dizziness, haematuria, epistaxis and pruritus (all n=1).
All AEs were reported as mild. All AEs except one were reported as unlikely to be related to trial products; haematuria (somapacitan 0.02 mg/ kg) was reported as possibly trial product related. There were no apparent treatment-dependent patterns in the type and frequency of AEs reported either within or among system organ classes.
Mean fasting plasma glucose levels (4.5-4.9 mmol/L) were within normal ranges for all dose groups, and no clinically relevant changes were observed during the trial period. The mean fasting insulin level was within the lower part of the normal ranges for all dose groups.
In the somapacitan 0.04, 0.08 and 0.16 mg/kg dose groups, the fasting blood glucose and fasting insulin increased initially from baseline to day 2, to decrease again towards baseline levels from days 2-7; all values were within the normal range. There were no changes towards abnormal clinically significant findings from screening in vital signs, physical examination or ECG in any of the treatment groups. No positive test results for antisomapacitan antibodies or anti-hGH antibodies were reported in the trial. 
| Local tolerability
| Pharmacokinetics
The mean serum concentration of somapacitan increased with dose following single-dose administration of children with GHD ( Figure 1 ).
Mean somapacitan AUC (0-168 h) , C max and t max increased with dose (Table 3) . Somapacitan AUC (0-168 h) and C max increased with increasing dose to a greater extent than would have been expected with dose
proportionality. The effect of doubling a dose was estimated to be 3.47 and 2.86 for AUC (0-168 h) and C max , respectively. A dose-dependent increase was observed in IGFBP-3 following somapacitan single-dose administration ( Figure 3A) . The reference range for IGFBP-3 is 2576-5777 ng/mL; baseline values of IGFBP-3 T A B L E 2 Adverse events occurring in ≥5% of patients exposed to somapacitan, by system organ class and preferred term Nervous system disorders
| Pharmacodynamics
Gastrointestinal disorders
%, percentage of exposed subjects having the event; AE, adverse event; E, number of AEs reported; N, number of subjects having the event at least once; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class. Planned time (days) 
| DISCUSSION
In this dose-escalation trial of somapacitan, a reversible albuminbinding GH derivative, the doses tested (0.02, 0.04, 0.08 and 0.16 mg/ kg) were well tolerated in children with GHD, with no clinically significant safety or local tolerability issues identified. All AEs except one were reported as unlikely to be related to trial products; only haematuria (somapacitan 0.02 mg/kg) was reported as possibly trial product related, but the investigator did not provide a hypothesis for this judgement. No antisomapacitan antibodies or anti-hGH antibodies were detected in the trial. Similar findings were reported in previous trials of somapacitan in healthy adult males (no antisomapacitan antibodies; hGH was not used) 11 and in AGHD patients (no antisomapacitan or anti-hGH antibodies). The half-life of somapacitan has been extended through noncovalent binding to endogenous albumin. A similar mechanism has been successfully employed to extend the half-life of insulin and GLP-1, 8, 9 with no associated significant tolerability issues. 9, 10 Several previous attempts have been made to develop a GH preparation that can be administered less frequently than once daily (summarized in Christiansen et al. 7 ). However, safety and tolerability issues have been associated with some long-acting GH formulations. For example, a pegylated GH formulation administered as once-weekly s.c. injections in children with GHD or AGHD was associated with significant lipoatrophy at the injection site in 12.4% of patients, 16 and a relatively high frequency of injection site reactions (30% in a single-dose study 17 and typically 39-50% in 6-to 12-month studies) has been observed in studies of long-acting formulations of GH, [18] [19] [20] although reactions are usually described as mild to moderate and/or transient. [18] [19] [20] [21] [22] One sustained-release GH injected once or twice monthly for 6 months or 2 years was accompanied by nodules (56%-60%), erythema (49%-54%) and postinjection pain (36%-37%). 23, 24 Treatment adherence may improve with longer-acting GH preparations compared with daily injections. Improved adherence
has not been proven and should ideally be compared in a randomized controlled trial. However, as the differences in adherence be- For the somapacitan dosing range tested in this trial (0.02-0.16 mg/kg), drug exposure parameters (C max and AUC) were dose dependent, although not dose proportional. In contrast, when somapacitan doses of 0.02-012 mg/kg were tested in adult patients with GHD, dose-proportional increases in PK parameters were observed, 12 and the increase in PK parameters appears to be influenced by body weight. The shape of the somapacitan profiles in children with GHD indicated nonlinear PK.
There was some variation in the baseline IGF-I SDS values across dose groups. The different IGF-1 baseline values after 7-10 days' washout may be due to the period of washout being too short for some of the children with GHD. When correcting for baseline IGF-I levels, the PD responses were dose dependent, with mean IGF-I SDS elevated for at least 7 days but remaining within the normal range, and thus supporting once-weekly dosing of somapacitan for the treatment of children with GHD. In a previous multiple-dose trial of somapacitan in adults with GHD, no IGF-I accumulation was observed; 12 however, in the current single-dose trial in children, accumulation was not addressed, and in some patients, IGF-I levels did not completely return to baseline after 7 days; this will therefore need to be addressed in a multiple-dose trial. As the IGF-I response to the somapacitan doses of 0.04, 0.08 and 0.16 mg/kg was comparable to the IGF-I response to Norditropin ® , these doses seem relevant for such a phase 2 dose finding study.
The C max of somapacitan after a single dose in this trial was be- It could be speculated that the use of a long-acting GH is less physiological than that of daily growth hormone injections and that permanently high GH concentrations could lead to downregulation and potentially less growth, affecting adult height. In the current study, the PK profile of once-weekly somapacitan revealed levels that were not permanently high, but varied throughout the week with a peak after approximately 2 days and a trough value after 7 days. Future clinical trials of longer duration need to determine whether long-term administration with somapacitan is as efficacious and safe as daily GH in children with GHD. A limitation of this trial was the small number of patients; however, childhood GHD is relatively uncommon, and a large sample size is not feasible. An unequal gender distribution between treatment groups could have affected the IGF-I results, and it has been suggested that response to GH with respect to IGF-I differs in prepubertal boys and girls; 27 however, the small sample sizes in the current trial did not permit analysis by gender. Further, the relatively low number of subjects limited the statistical interpretation of the data, and variations of the IGF-I baseline levels also made interpretation difficult. It is also worth noting that this was a single-dose trial resulting in short-term exposure to somapacitan on which the reported safety, PK and PD data are based; the long-term effects of somapacitan on IGF-I levels and adverse event profile are more likely to be observed in future long-term trials.
In conclusion, single doses of somapacitan within the dose range 0.02-0.16 mg/kg were well tolerated when administered to prepubertal children with GHD. No clinically significant safety signals causally related to somapacitan were identified, nor were any immunogenicity concerns revealed. The IGF-I profile indicates that somapacitan is suitable for once-weekly dosing in children with GHD. 
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